CASI Pharmaceuticals, Inc. engages in developing and commercializing therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 176 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Industry: Biological Products, (No Diagnostic Substances) Peers: Acurx Pharmaceuticals Inc Protara Therapeutics Inc Orgenesis Inc. Cyclerion Therapeutics Inc PhaseBio Pharmaceuticals Inc Eledon Pharmaceuticals Inc Gain Therapeutics Inc Molecular Templates, Inc. Tracon Pharmaceuticals, Inc.